diluted weighted average shares outstanding for both of these periods
for purposes of computing diluted earnings per share.
GENZYME CORPORATION (GENZ)
Condensed Consolidated Balance Sheets March 31, December 31,
(Unaudited, amounts in thousands) 2008 2007
Cash and all marketable securities $1,447,983 $1,460,394
Other current assets 1,818,541 1,661,740
Property, plant and equipment, net 2,118,960 1,968,402
Intangibles, net (1) 3,386,451 2,959,480
Other assets (2) 311,581 251,725
Total assets $9,083,516 $8,301,741
Current liabilities $1,475,663 $1,502,406
Noncurrent liabilities (1) 658,936 186,398
Stockholders' equity 6,948,917 6,612,937
Total liabilities and stockholders'
equity $9,083,516 $8,301,741
(1) Effective January 1, 2008, in connection with the restructuring of
BioMarin/Genzyme LLC, our joint venture with BioMarin Pharmaceutical
Inc., we licensed certain rights to commercialize Aldurazyme from the
joint venture and, in accordance with the provisions of FASB
Interpretation No. 46R, "Consolidation of Variable Interest Entities,"
began consolidating the results of the joint venture at fair value. As
of March 31, 2008, intangibles, net, includes $480,500K for the fair
value of the joint venture's manufacturing and commercialization
rights to Aldurazyme, offset by $(6,006)K of related accumulated
amortization. Noncurrent liabilities includes $474,494K of additional
net liabilities relat
|SOURCE Genzyme Corp.|
Copyright©2008 PR Newswire.
All rights reserved